Carglumic Acid Market Size (2024 - 2029)

The carglumic acid market is anticipated to experience growth due to increasing demand driven by its use in treating conditions like hyperammonemia, particularly in COVID-19 patients. The market size is influenced by rising cases of metabolic disorders and liver-related diseases, which necessitate the use of carglumic acid. Additionally, the drug's application in managing ammonia levels due to alcohol consumption and smoking-related diseases further contributes to market expansion. Despite these growth drivers, the market faces challenges such as high costs of patented products and potential side effects of the medication, which may hinder its growth potential.

Market Size of Carglumic Acid Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Carglumic Acid Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 7.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Carglumic Acid Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Carglumic Acid Market Analysis

The Carglumic Acid Market is projected to register a CAGR of 7.2% during the forecast period.

COVID-19 brought a high infection rate among the population across the globe.The medical emergency known as hyperammonemia results in cerebral edema and neurologic impairment. Due to hyperammonemia from a disseminated cryptococcal infection, respiratory distress syndrome in COVID-19 patients may be the cause of such an infection.A rare genetic condition characterized by a lack of N-acetylglutamate synthase (NAGS) can be treated with the orphan medication carglumic acid, which aids in converting ammonia into urea in patients. This condition is creating a demand for carglumic acid medications for patients suffering from COVID-19 infections. Due to a deficit in the hepatic enzyme NAGS, it was utilized as a supplementary therapy for the treatment of acute hyperammonemia and as a maintenance therapy for chronic hyperammonemia. Hence, the COVID-19 pandemic significantly impacted the market.

The main things that are driving the growth of the carglumic acid market are the rise in cancers caused by drinking, smoking, and being inactive, as well as the rise in metabolic disorders like hepatic encephalopathy, Reye's syndrome, and cirrhosis around the world.WHO's key facts, which were last updated in May 2022, say that drinking too much can cause more than 200 diseases and injuries.According to the same source as above, alcohol-related disabilities caused 5.1% of the world's disease and injury burden in 2022.The amount of ammonia in the blood rises as people drink more alcohol. Carglumic acid is used and prescribed to lower the amount of ammonia in the blood.This is expected to drive the market.

In the same way, more people smoking and the problems that come with smoking are likely to increase the use of carglumic acid and help the market grow.For instance, according to the Office on Smoking and Health and the Chronic Disease Center (NCCDPHP), whose data was updated in March 2022, nearly 13 of every 100 United States adults aged 18 years or older (12.5%) smoked cigarettes in 2020. This means an estimated 30.8 million adults in the United States currently smoke cigarettes. More than 16 million Americans live with a smoking-related disease. Therefore, the smoking-related disease burden is anticipated to create demand for arglumic acid products, further fueling the market's growth.

In addition, hepatic encephalopathy (HE) is a nervous system disorder that is caused by severe liver disease and is often treated with carglumic acid. The number of people with covert hepatic encephalopathy (CHE) goes up to 54% when minimal hepatic encephalopathy (MHE) is found, according to an article in the Clinical Gastroenterology and Hepatology journal from August 2022.This burden of HE is expected to drive market growth. Additionally, according to the National Institute of Neurological Disorders and Stroke (NINDS) data published in February 2022, an estimated two children per year in the United States develop Reye's syndrome. This is expected to accumulate ammonia in the blood and thereby increase growth. Also, carglumic acid has shown potential for anti-tumor activity in breast cancer, along with various applications in cosmetics and chemicals, which are expected to fuel the global carglumic acid market during the forecast period.

But the market isn't growing as fast as it could because there are more problems in the development stage, patented products are expensive, and carglumic acid medicines can have serious side effects.

Carglumic Acid Industry Segmentation

As per the scope of the report, carglumic acid is an orphan drug used to treat hyperammonemia also known as NAGS Syndrome, a rare genetic disorder that occurs due to the lack of an enzyme called N-acetyl glutamate synthase (NAGS) in the liver, that results in elevated levels of ammonia in the blood causing hyperammonemia. The Carglumic Acid Market is segmented by Dosage Form (Orally Disintegrating Tablets, Dispersible Tablets, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce Channel), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Dosage Form
Orally Disintegrating Tablets
Dispersible Tablets
Other Dosage Forms
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Channel
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Carglumic Acid Market Size Summary

The carglumic acid market is poised for significant growth, driven by its application in treating rare genetic conditions and metabolic disorders. This orphan medication is crucial for patients lacking the N-acetylglutamate synthase enzyme, aiding in ammonia conversion to urea. The COVID-19 pandemic has further amplified its demand, as hyperammonemia complications in infected patients necessitate its use. The rising prevalence of alcohol-related diseases, smoking-related conditions, and metabolic disorders like hepatic encephalopathy and Reye's syndrome are also contributing to market expansion. Additionally, carglumic acid's potential anti-tumor activity and applications in cosmetics and chemicals are expected to bolster its market presence.

North America is anticipated to dominate the carglumic acid market, supported by increasing cancer incidences and hyperammonemia cases. The region benefits from robust pharmaceutical research and regulatory support, ensuring product safety and efficacy. The market is moderately competitive, with key players like Apothecon Pharmaceuticals and Recordati Rare Diseases Inc. leading the charge. Recent approvals and product launches, such as the USFDA's endorsement of carglumic acid tablets, are set to enhance market dynamics. Despite challenges like high development costs and potential side effects, the demand for dispersible tablets and the growing patient population with NAGS syndrome and related disorders are expected to drive segmental growth during the forecast period.

Explore More

Carglumic Acid Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Global Prevalence of N-acetylglutamate Synthase (NAGS) Syndrome and Cancer Cases

      2. 1.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA

    3. 1.3 Market Restraints

      1. 1.3.1 Severe Adverse Effects Associated with Carglumic Acid Medication

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Dosage Form

      1. 2.1.1 Orally Disintegrating Tablets

      2. 2.1.2 Dispersible Tablets

      3. 2.1.3 Other Dosage Forms

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospital Pharmacies

      2. 2.2.2 Retail Pharmacies

      3. 2.2.3 E-Commerce Channel

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Carglumic Acid Market Size FAQs

The Carglumic Acid Market is projected to register a CAGR of 7.20% during the forecast period (2024-2029)

Apothecon Pharmaceuticals Pvt. Ltd, Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc, Civentichem LLC and Dipharma Francis S.r.l are the major companies operating in the Carglumic Acid Market.

Carglumic Acid Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)